Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

NCT02066415 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02066415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2014
Completion date
April 28, 2016
Enrollment
667 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

treatment for prevention of chronic migraine